Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024
PACIFIC (PACB.O, NASDAQ Cons)
Závěr k 28.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
3,75 0,81 0,03 6 566 469
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiPacific Biosciences of California Inc
TickerPACB
Kmenové akcie:Ordinary Shares
RICPACB.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 796
Akcie v oběhu k 31.01.2024 267 951 880
MěnaUSD
Kontaktní informace
Ulice1305 O'brien Drive
MěstoMENLO PARK
PSČ94025
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 505 218 000
Fax13026365454

Business Summary: Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Pacific Biosciences of California Inc revenues increased 56% to $200.5M. Net loss decreased 2% to $306.7M. Revenues reflect Instrument revenue segment increase from $48.7M to $120.5M, Consumable revenue segment increase of 6% to $63.4M, North America segment increase of 52% to $105.4M, Asia Pacific segment increase of 51% to $54.5M. Lower net loss reflects Other income, net increase from $7.6M to $32.7M (income).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
NAICS2007Electromedical Apparatus Mfg
NAICS2007Analytical Laboratory Instrument Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Analytical Laboratory Instrument Manufacturing
SICAnalytical Instruments
SICElectromedical Equipment
SICAnalytical Instruments



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorChristian Henry5514.09.202002.03.2020
Chief Financial OfficerSusan Kim4728.09.202028.09.2020
Chief Operating OfficerMark Van Oene5008.01.202108.01.2021
Chief Accounting Officer, Vice PresidentMichele Farmer-17.05.202117.05.2021
General Counsel, Corporate SecretaryBrett Atkins-
Chief Commercial OfficerJeff Eidel4616.08.202216.08.2022